UroGen Pharma Shares Plunge After FDA Advisory Committee Rejects UGN-102 Treatment UroGen Pharma Ltd. faces serious losses as shares drop 44% following a negative FDA committee vote on UGN-102, raising investor concerns.

UroGen Pharma Shares Plunge After FDA Advisory Committee Rejects UGN-102 Treatment #United_States #San_Francisco #UroGen_Pharma #UGN-102 #FDA_Advisory